Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
J. Salvador,Luís Manso,Juan de la Haba-Rodríguez,A. Jaén,Eva Ciruelos,Marco Villena,Mireia Gil-Raga,A Murias,António Galán de Mera,Carlos Jara,Juan L. Bayo,José Manuel Baena,J. Casal,J. R. Mel,Isabel Blancas,P. Sanchez Rvira